CJC-1295 (No DAC) vs PT-141 (Bremelanotide)
CJC-1295 (No DAC) and PT-141 (Bremelanotide) are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: CJC-1295 (No DAC) is ghrh(1-29) tetra-substituted analogue (dac-free), while PT-141 (Bremelanotide) is cyclic heptapeptide, melanocortin receptor agonist — different molecular classes with different handling consequences; their leading degradation routes differ (deamidation at asn/gln residues over long solution storage. for CJC-1295 (No DAC), tryptophan photo-oxidation for PT-141 (Bremelanotide)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
CJC-1295 (No DAC) — origin
CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.
PT-141 (Bremelanotide) — origin
PT-141 is a metabolite of Melanotan II, and its history is an unusually direct case of a side effect becoming the research programme. Melanotan II was developed as a synthetic α-MSH analogue for pigmentation research; an unanticipated effect observed during that work redirected attention to the metabolite, which was then developed separately as bremelanotide.
CJC-1295 (No DAC) research themes
Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.
The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.
Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.
PT-141 (Bremelanotide) research themes
Acts at melanocortin receptors, with MC3R and MC4R the subtypes of research interest.
Distinguished in the literature by acting centrally, unlike vascular-mechanism compounds in adjacent research areas.
Its origin as a metabolite of a pigmentation-research compound is central to understanding its development history.
The lactam bridge restricts conformational freedom, a common strategy for improving receptor selectivity.
CJC-1295 (No DAC) handling
- Reach room temperature before opening.
- Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
- Aliquot and refrigerate; never re-freeze reconstituted solution.
PT-141 (Bremelanotide) handling
- Protect from light at all stages.
- Standard gentle reconstitution; the constrained ring is not agitation-sensitive in the way flexible long chains are.
- Store refrigerated and aliquot rather than repeatedly sampling one vial.
Both third-party tested
Every Popular Peptides batch of CJC-1295 (No DAC) and PT-141 (Bremelanotide) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
CJC-1295 (No DAC) reference
Related comparisons
CJC-1295 (No DAC) and PT-141 (Bremelanotide) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.